{
    "clinical_study": {
        "@rank": "60210", 
        "arm_group": {
            "arm_group_label": "Group 1"
        }, 
        "brief_summary": {
            "textblock": "This study is a post-marketing surveillance in Japan, and it is a local prospective and\n      observational study of patients who have received Ciproxan intravenously as a first-line\n      treatment for sepsis, secondary skin infections followed by superficial burn, post-surgical\n      or post-traumatic, pneumonia, peritonitis, cholecystitis, cholangitis, anthrax. The\n      objective of this study is to assess safety and efficacy of Ciproxan in daily clinical\n      practice. A total of 3,000 patients are to be enrolled and assessed during the period of\n      treatment with Ciproxan."
        }, 
        "brief_title": "Assessment of the Safety and Efficacy of Ciproxan-I.V. in Daily Clinical Practice - Analysis Results From a Post-marketing Surveillance", 
        "completion_date": {
            "#text": "October 2010", 
            "@type": "Actual"
        }, 
        "condition": "Infection", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients who received Ciproxan as a first-line treatment were eligible for the study,\n             among those with sepsis, secondary infection due to trauma, burn, or surgical wound,\n             pneumonia, peritonitis, cholecystitis, cholangitis, and anthrax as the indications of\n             this drug.\n\n        Exclusion Criteria:\n\n          -  Patients who are contraindicated based on the product label."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "7 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients who received Ciproxan as a first-line treatment were eligible for the study,\n        among those with sepsis, secondary infection due to trauma, burn, or surgical wound,\n        pneumonia, peritonitis, cholecystitis, cholangitis, and anthrax as the indications of this\n        drug."
            }
        }, 
        "enrollment": {
            "#text": "3274", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 7, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01670435", 
            "org_study_id": "15029", 
            "secondary_id": "CIPRO-IV-2007"
        }, 
        "intervention": {
            "arm_group_label": "Group 1", 
            "description": "Patient treated with Ciproxan as a first line treatment in daily clinical practice", 
            "intervention_name": "Ciprofloxacin (BAYQ3939)", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Ciprofloxacin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Ciprofloxacin", 
            "sepsis", 
            "infection", 
            "pneumonia", 
            "peritonitis", 
            "cholecystitis", 
            "cholangitis", 
            "anthrax"
        ], 
        "lastchanged_date": "August 27, 2012", 
        "link": [
            {
                "description": "Click here and search for drug information provided by the FDA.", 
                "url": "http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm"
            }, 
            {
                "description": "Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.", 
                "url": "http://www.fda.gov/medwatch/safety.htm"
            }
        ], 
        "location": {
            "facility": {
                "address": {
                    "city": "Many Locations", 
                    "country": "Japan"
                }
            }
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_groups": "1", 
        "official_title": "Assessment of the Safety and Efficacy of Ciproxan-I.V. in Daily Clinical Practice - Analysis Results From a Post-marketing Surveillance", 
        "overall_official": {
            "affiliation": "Bayer", 
            "last_name": "Bayer Study Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2010", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Incidence of adverse drug reactions (ADRs) and serious adverse events (AEs)", 
                "safety_issue": "Yes", 
                "time_frame": "After 9 days"
            }, 
            {
                "measure": "Clinical efficacy by four grade (Response, Minor Response, No Response, and Indeterminable) at an investigator discretion", 
                "safety_issue": "No", 
                "time_frame": "After 9 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01670435"
        }, 
        "responsible_party": {
            "name_title": "Medical Director", 
            "organization": "Bayer Yakuhin, Ltd."
        }, 
        "secondary_outcome": [
            {
                "measure": "ADR incidence rates classified by patient's background factors", 
                "safety_issue": "Yes", 
                "time_frame": "After 9 days"
            }, 
            {
                "measure": "Efficacy rate calculated with Response and Minor Response considered as responder", 
                "safety_issue": "No", 
                "time_frame": "After 9 days"
            }, 
            {
                "measure": "Efficacy rates classified by patient's background factors", 
                "safety_issue": "No", 
                "time_frame": "After 9 days"
            }
        ], 
        "source": "Bayer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2007", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "August 2012"
    }
}